Key Points {#d30e230}
==========

Inappropriate drug use (IDU) was associated with hospitalization in older persons and in persons with dementia.IDU was also associated with mortality among older persons.There was a tendency for higher costs for hospitalizations with IDU than without IDU, although the difference was not statistically significant.

Introduction {#Sec1}
============

The proportion of older persons is increasing worldwide \[[@CR1]\]. People aged 60 years and older will increase from 10 % in 2001 to more than 21 % in 2050 \[[@CR1], [@CR2]\]. This aging of populations brings major challenges for healthcare systems and for societies' resource allocation. One of these challenges is appropriate drug prescribing to older persons.

Drug prescribing to older patients is extensive \[[@CR3]\], although old age is a risk factor for adverse drug reactions \[[@CR4]\]. Certain drug treatment that is appropriate for younger or middle-aged patients can be inappropriate in old age due to age-related changes in pharmacokinetics and pharmacodynamics together with organ failure \[[@CR4]\]. Inappropriate drug use (IDU), e.g., long-acting benzodiazepines, anticholinergic drugs, and drug combinations that may lead to serious drug--drug interactions \[[@CR5]\], is defined as drug therapy that poses potential risks that outweigh potential benefits \[[@CR6]\]. Still, IDU is common among older persons \[[@CR5]\] and has been associated with health, clinical, and economic outcomes \[[@CR7]\]. The two most serious outcomes of IDU are hospitalizations and mortality. We therefore focused on these with the added value of an estimation of cost outcomes.

Previous research about IDU and risk of hospitalizations and mortality \[[@CR8]--[@CR10]\] has often been limited by lack of information about important clinical variables, such as dementia, or by analysis of small and selected samples. Cost analysis of IDU has so far been scarce \[[@CR11]\], although this research is important from a stakeholder and resource allocation perspective. Thus, we aimed to investigate IDU and risk of hospitalizations and mortality in older persons and in persons with dementia in a population of community-dwelling and institutionalized individuals. We also aimed to estimate the costs of IDU-related hospitalizations.

Methods {#Sec2}
=======

Study Population {#Sec3}
----------------

Data for this study were obtained from the ongoing, longitudinal cohort study Swedish National Study on Aging and Care (SNAC), which is described in detail elsewhere \[[@CR12]\]. In short, SNAC is a study conducted at four sites in Sweden (Nordanstig, Kungsholmen, Karlskrona, and four municipalities in Skåne), reflecting both rural and urban parts of Sweden. People aged 60 years and over in certain age groups (60, 66, 72, 78, 81, 84, 87, 90, 93, 96, 99 years) were recruited for an extensive examination, which included a physical examination and medical history by a physician. Interviews covering a wide range of areas such as socioeconomic factors, physical environment, and care service utilization were also conducted by a nurse, and tests of psychological status and cognitive performance were made by a psychologist. The data used in this study were collected at baseline during the years 2001--2004 in Nordanstig, a rural area in the middle of Sweden, and Kungsholmen, an urban area in Stockholm (*n* = 4129).

Sociodemographic Variables {#Sec4}
--------------------------

Age was categorized into 60--69, 70--79, 80--89, and ≥90 years in the descriptive analysis and used as a continuous variable in the regression models. Residential setting was dichotomized into community dwelling (i.e., living in one's own home) versus institution (sheltered accommodation, old people's home, group dwelling, or nursing home). Educational level was classified into elementary versus additional schooling.

Drug Use {#Sec5}
--------

Use of drugs was recorded by the physician and the participants were asked to bring current lists of medications, drug containers, and prescriptions. If the participant was not able to answer, an informant close to the person (relative or carer) was asked to provide the information. Drug use was defined as use of a drug regularly at the time of the interview or as needed at any time during the preceding month. Regular use was defined as the use of a drug on a scheduled basis (e.g., day, week, or fortnight). Data on both prescribed drugs and over-the-counter drugs were collected \[[@CR12]\]. The dose and frequency of the drugs used were also collected. Polypharmacy was defined as use of five or more drugs regularly. Drugs were classified according to the anatomical therapeutic and chemical (ATC) system \[[@CR13]\].

Inappropriate Drug Use (IDU) {#Sec6}
----------------------------

IDU was defined according to the indicators developed by the Swedish National Board of Health and Welfare \[[@CR5], [@CR14], [@CR15]\]: concurrent use of three or more psychotropic drugs (from any of the groups antipsychotics, anxiolytics, hypnotics-sedatives, and antidepressants), use of drugs with anticholinergic properties (urinary and gastrointestinal antispasmodics, anticholinergic antiemetics, class Ia antiarrhythmics, anticholinergic antiparkinsonian drugs, low-potency antipsychotics, tricyclic antidepressants, and first-generation antihistamines), use of long-acting benzodiazepines (diazepam, nitrazepam, or flunitrazepam), and serious drug--drug interactions according to the system by Sjöqvist \[[@CR16]\]. IDU was defined as exposure to at least one of these four indicators \[[@CR5]\].

Dementia {#Sec7}
--------

Dementia was diagnosed by physicians according to the *Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised* (DSM-III-R) \[[@CR17]\].

Co-Morbidity {#Sec8}
------------

We used the Charlson Comorbidity Index, which is often used to adjust for confounding by co-morbidities \[[@CR18]\]. The version applied in this study was adapted to the availability of data \[[@CR8]\]. We used seven diagnoses with a weight of one (congestive heart failure, myocardial infarction, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disorder, and diabetes mellitus without complication) and two diagnoses with a weight of two (moderate or severe renal failure and any tumor), which gives a maximum total of 11. The comorbidity index was entered as a dichotomous variable in the analysis (none vs. one or more modified Charlson Comorbidity Index weights).

Diagnoses of diseases in the index were all based on medical history and examination of the physician except renal failure and dementia. Renal failure was calculated from Cockcroft-Gault formula \[[@CR19]\] and defined as estimated creatinine clearance \<25 mL/min. Dementia diagnosis is included in the Charlson Comorbidity Index, but dementia was analyzed as a separate variable in the regression analysis and was, thus, removed from the index.

Physical Functioning {#Sec9}
--------------------

Physical functioning was assessed by the Katz index of activities of daily living (ADL) \[[@CR20]\]. The Katz ADL is a scale that measures functional dependency in six basic activities: transferring, dressing, bathing, going to the toilet, feeding, and continence. Functional independence was defined as no need of assistance and dependent was defined as being dependent in one or more activities.

Hospitalizations and Mortality {#Sec10}
------------------------------

Data on mortality and hospitalizations were collected from registers at the Swedish National Board of Health and Welfare. Both death certificates and data on hospitalization were collected from individual entrance into the study until 1 year after the last date of inclusion in the study.

Costs of Hospitalization {#Sec11}
------------------------

Cost data of hospitalization were derived from the Nord-Diagnose Related Group (DRG) cost database \[[@CR21]\]. This is a Swedish version of the original Diagnosis Related Group (DRG) database \[[@CR22]\], which was produced to rationalize cost-finding for budgeting and visualize costing for practitioners. Each DRG code was derived from the corresponding International Classification of Diseases (ICD) code \[[@CR23]\] with a specific weight. This weight was then multiplied by the DRG cost of weight 1 in order to calculate the total cost of the hospitalization.

Any health economic analysis needs to have a specified viewpoint \[[@CR24]\]. This paper focuses on costs of hospitalizations, which is a part of medical sector costs. Costs of the community care sector and costs of informal care are therefore not included. Furthermore, the only additional outcome was mortality. No other effects, such as quality of life or functional capacity, were included. The basic health economic design is descriptive and there is no predefined hypothesis regarding cost effectiveness. Thus, the health economic approach in this paper can be regarded as a cost description that can generate hypotheses for interventions regarding IDU.

Statistical Analysis {#Sec12}
--------------------

Descriptive demographic statistics were made with cross-tabulations. Logistic regression analysis was used to investigate the association between IDU and hospitalizations within 1 year of assessment of IDU, after adjustment for covariates. Similarly, Cox regression models were used for analysis of IDU and mortality within 1 year of assessment of IDU, after adjustment for covariates. The outcomes hospitalizations and mortality were analyzed in the whole study population and in the subpopulation of persons with dementia. There were no significant differences in IDU between the two sites, Nordanstig and Kungsholmen, and inclusion of site did not affect the results of the regression models; thus, this variable was not included in the analyses. The results are shown as odds ratios (ORs) and hazard ratios (HRs) with 95 % confidence intervals (95 % CIs). We used one-way analysis of variance (ANOVA) to explore differences in mean cost of hospitalizations with and without IDU, after adjustment for age. A *p* value of \<0.05 was considered statistically significant. All analysis was made with IBM SPSS^®^ Statistics version 22 \[[@CR25]\].

Ethics {#Sec13}
------

The study was approved by the ethical review board in Stockholm (dnr 01-114, dnr 2009/595-32) and in Uppsala (dnr 01-123). Informed consent was obtained from all participants included in the study.

Results {#Sec14}
=======

The characteristics of the study participants are shown in Table [1](#Tab1){ref-type="table"}. Of the 4129 participants, 21 did not have information on drug use and were therefore excluded from the analyses (*n* = 4108). The mean age of the population was 74.8 years \[standard deviation (SD) = 11.1; range = 60--105 years) and 81 % used at least one drug. The mean number of drugs used was 3.6 (SD = 3.4; range 0--23) and the proportion of persons with polypharmacy (use of five or more drugs) was 33 %. The overall prevalence of IDU was 13 %; 27 % among persons with dementia and 12 % among persons without dementia (*p* \< 0001). Women were more often exposed to IDU than men (15 vs. 10 %; *p* \< 0.001). The prevalence of IDU in institutions was 34 % and among community dwellers 12 % (*p* \< 0.001). In people with functional dependency in ADL, the prevalence was higher (27 %) than in people with functional independence (11 %) (*p* \< 0.001).Table 1Population characteristics and prevalence of inappropriate drug useCharacteristicTotal no. of participantsNo. of participants with IDUPrevalence of IDU (%)All410853613.0Age (years; continuous) 60--6915591217.8 70--79112716114.3 80--8987215117.3 ≥9055010318.7Sex Men152815710.3 Women258037914.7Education^a^ Elementary109814313.0 Additional297638813.0Residential setting Community dwelling382644011.5 Institution2829634.0Dementia^b^ No378344511.8 Yes3198727.3Charlson Comorbidity Index 024142309.5 174711915.9 264010616.6 ≥33078126.4Number of drugs 0--11346110.8 2--413901198.6 ≥5137240629.6Katz ADL Independent365140411.3 Dependent40911227.4*ADL* activities of daily living, *IDU* inappropriate drug use^a^Missing data on education for 34 persons^b^Missing data on dementia status for 6 persons^c^Missing data on Katz ADL for 48 persons

IDU was associated with a higher risk of hospitalization within 1 year (adjusted OR = 1.46; 95 % CI 1.18--1.81), after adjustment for age, sex, dementia, residential setting, educational level, physical functioning, and co-morbidity (Table [2](#Tab2){ref-type="table"}). Also higher age, male sex, living at home (community dwelling), lower educational level, functional dependence, and a higher level of co-morbidity were associated with higher odds for hospitalization within 1 year.Table 2Multivariate logistic regression analysis of the association between inappropriate drug use and hospitalization within 1 yearCharacteristicOR95 % CIAge (years; continuous)1.041.03--1.05Sex MaleReference Female0.800.67--0.92Dementia NoReference Yes0.970.68--1.39Residential setting Community dwellingReference Institution0.250.16--0.38Education ElementaryReference Additional0.720.61--0.86Katz ADL IndependentReference Dependent2.151.58--2.92Co-morbidity No co-morbiditiesReference Co-morbidities1.351.15--1.58IDU NoReference Yes1.461.18--1.81Multivariate logistic regression is adjusted for all variables in the table; data missing for 52 persons*ADL* activities of daily living, *CI* confidence interval, *IDU* inappropriate drug use, *OR* odds ratio

IDU was also associated with an increased risk of mortality within 1 year (adjusted HR = 1.15; 95 % CI 1.01--1.31), after adjustment for age, sex, dementia, residential setting, educational level, physical functioning, co-morbidity, and hospitalization within 1 year (Table [3](#Tab3){ref-type="table"}). The greatest risk factors for mortality were higher age, co-morbidity, hospitalization within 1 year, male sex, and dementia.Table 3Multivariate Cox proportional hazard regression analysis for inappropriate drug use and risk of mortality within 1 yearCharacteristicHR95 % CIAge (years; continuous)1.071.06--1.08Sex MaleReference Female0.760.68--0.84Dementia NoReference Yes1.281.08--1.52Residential setting Community dwellingReference Institution1.090.90--1.52Education ElementaryReference Additional0.930.83--1.03Katz ADL IndependentReference Dependent1.181.01--1.39Co-morbidity No co-morbiditiesReference Co-morbidities1.411.27--1.56Hospitalization within 1 year NoReference Yes1.371.23--1.53IDU NoReference Yes1.151.01--1.31Multivariate Cox proportional hazard regression is adjusted for all variables in the table; data missing for 52 persons*ADL* activities of daily living, *CI* confidence interval, *HR* hazard ratio, *IDU* inappropriate drug use

Among the 319 persons with dementia (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}), IDU was associated with a higher risk of hospitalization within 1 year (adjusted OR = 1.88; 95 % CI 1.03--3.43), but not statistically significantly associated with mortality (adjusted HR = 1.13; 95 % CI 0.87--1.47). Furthermore, the only additionally detected statistically significant associations among the individuals with dementia were between living in an institution and hospitalization (adjusted OR = 0.26; 95 % CI 0.13--0.50) and between age (continuous variable) and mortality (adjusted HR = 1.02; 95 % CI 1.00--1.04).Table 4Multivariate logistic regression analysis for the association between inappropriate drug use and hospitalization within 1 year in people with dementiaCharacteristicOR95 % CIAge (years; continuous)1.010.97--1.05Sex MaleReference Female0.870.45--1.71Residential setting Community dwellingReference Institution0.260.13--0.50Education ElementaryReference Additional0.900.55--1.57Katz ADL IndependentReference Dependent1.190.61--2.30Co-morbidity No co-morbiditiesReference Co-morbidities1.470.89--2.63IDU NoReference Yes1.881.03--3.43Multivariate logistic regression is adjusted for all variables in the table; data missing for 17 persons*ADL* activities of daily living, *CI* confidence interval, *IDU* inappropriate drug use, *OR* odds ratioTable 5Multivariate Cox proportional hazard regression analysis for inappropriate drug use and risk of mortality in people with dementiaCharacteristicHR95 % CIAge (years; continuous)1.021.00--1.04Sex MaleReference Female0.990.73--1.04Residential setting Community dwellingReference Institution0.990.74--1.33Education ElementaryReference Additional1.120.89--1.41Katz ADL IndependentReference Dependent1.250.93--1.70Co-morbidity No co-morbiditiesReference Co-morbidities1.110.88--1.41Hospitalization within 1 year NoReference Yes1.100.84--1.44IDU NoReference Yes1.130.87--1.47Multivariate Cox proportional hazard regression is adjusted for all variables in the table; data missing for 17 persons*ADL* activities of daily living, *CI* confidence interval, *HR* hazard ratio, *IDU* inappropriate drug use

Table [6](#Tab6){ref-type="table"} shows the costs for hospitalization stratified by IDU and dementia status. There was a tendency for higher costs of hospitalizations with IDU, although it was not statistically significant in any group.Table 6Costs of hospitalization in people with and without inappropriate drug use stratified by dementia status (*n* = 4108)No dementia95 % CIDementia95 % CICost for hospitalization without IDU (mean ± 95 % CI) \[SEK\]13,36211,934--14,79018,72711,904--25,549Cost for hospitalization with IDU (mean ± 95 % CI) \[SEK\]19,52316,924--22,12320,36214,344--26,379*CI* confidence interval, *IDU* inappropriate drug use, *SEK* Swedish krona

Discussion {#Sec15}
==========

Main Findings {#Sec16}
-------------

This study is one of few studies that have examined the association between IDU, hospitalization, and mortality in a population-based setting with an added estimation of the costs of IDU.

The overall prevalence of IDU was similar to findings from Swedish national data \[[@CR26]\], but slightly lower that reported in a previous study by Klarin et al. \[[@CR8]\] based on Nordanstig data collected in 1995--1998 and based on an older study population. Compared to international studies, our prevalence of IDU is within the range of previous reports \[[@CR27]\], although at the lower end \[[@CR28], [@CR29]\]. The differences in prevalence estimates of IDU may be explained by differences in inclusion of age groups, IDU criteria, setting, design, and sampling techniques, e.g., convenience samples of old hospitalized patients may over-report IDU given that these frail persons are often a particularly exposed group \[[@CR30]\].

We found that IDU was associated with a higher risk of hospitalization and mortality among older persons, after adjustment for sociodemographic, functional, and co-morbidity variables. This is in line with previous research \[[@CR9], [@CR10], [@CR28], [@CR30], [@CR31]\]. However, the previous study by Klarin et al. \[[@CR8]\], which was based on rural Nordanstig data, showed an association of IDU only with hospitalizations but not with mortality. Our study with the inclusion of the Kungsholmen area and with a lower age limit is much larger and hence more statistically well-powered. To our knowledge, this is one of the first studies to show that IDU increases the risk of hospitalizations and mortality within the same study. IDU is an important risk factor for adverse drug reactions \[[@CR32]\], which in turn can lead to hospitalizations and, in the worst-case scenario, to increased mortality. Therefore, our study gives support to the growing evidence of detrimental outcomes of inappropriate prescribing to older patients and support limited use of these drugs.

For people with dementia, IDU was associated with a higher risk of hospitalization. However, the association between IDU and mortality was not statistically significant, although the effect estimate was of the same magnitude as that of the whole study population. More studies of IDU in dementia cohorts are needed to confirm our findings about outcomes of IDU in this vulnerable group of persons \[[@CR33]\].

Our study shows a higher prevalence of IDU in institutions than in the community-dwelling setting. Haasum et al. \[[@CR26]\] has previously shown that institutionalization may be a risk factor for IDU. These results underline the need for cautious prescribing in this population of frail older persons. Female sex has also previously been related to IDU \[[@CR34]\], which is in line with our study.

We found a tendency for higher costs for hospitalizations with IDU than without IDU, although it was not statistically significant. Estimation of costs of IDU is difficult and is often reported as the costs for the drugs involved \[[@CR35], [@CR36]\]. In our study, the costs of IDU were measured as costs for hospitalizations and we therefore report higher costs than previous studies. Indeed, a recent review article concludes that hospital costs are the main cost driver and that they are partly preventable \[[@CR11]\].

Strengths and Limitations {#Sec17}
-------------------------

The great strength of this study is the population-based design with the possibility to adjust for many important confounders.

IDU was assessed at baseline and not at time of hospitalization or death. Hence, IDU could have been introduced or discontinued during this period. Therefore, we chose the rather narrow time period of 1 year between IDU assessment and the two outcomes in order to limit the possible misclassification of exposure. This may both over- and underestimate the risk of mortality.

The overall response rate in Kungsholmen was about 73 % and in Nordanstig 75 %. There was no difference in the sex distribution between non-responders and responders in Kungsholmen, whereas there were slightly more responders among men than women in Nordanstig.

Confounding by indication may be present in our study, although we adjusted for physical dependence, dementia, and co-morbidity. In the analysis of mortality, we also adjusted for hospitalization within 1 year as a proxy for disease severity.

A risk with self-reported drug use is recall bias, but the advantages over pharmacy claims data include information closer to adherence, i.e., data were based on drugs that were actually taken, not only purchased, and that over-the-counter drugs are included.

Another limitation was that the cost viewpoint was restricted to hospitalization costs. There are also post-hospitalization costs in terms of informal care and community services as well as suffering in terms of an impaired quality of life due to IDU, which are difficult to analyze.

Conclusions {#Sec18}
===========

Our findings suggest that IDU is associated with an increased risk of hospitalization in older persons and in persons with dementia. IDU is also associated with mortality among older persons. These findings highlight the need for cautious prescribing of long-acting benzodiazepines, anticholinergic drugs, concurrent use of three or more psychotropic drugs and drug combinations that may lead to serious drug--drug interactions to older patients. Further studies are needed to investigate the association between IDU and costs for hospitalizations.
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